We are live on
!
Find out more
EC
EntryPoint Capital Portfolio holdings
AUM
$341M
1-Year Est. Return
20.57%
This Fund
S&P 500
This Quarter
Est. Return
-8.17%
1 Year Est. Return
+20.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$218M
AUM Growth
-$19.5M
(-8.2%)
Cap. Flow
+$3.51M
Cap. Flow
% of AUM
1.61%
Top 10 Holdings %
Top 10 Hldgs %
4.42%
Holding
1,001
New
307
Increased
177
Reduced
167
Closed
349
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$934K |
| 2 |
MASI
Masimo
MASI
|
+$931K |
| 3 |
Palladyne AI
PDYN
|
+$929K |
| 4 |
Equity Lifestyle Properties
ELS
|
+$926K |
| 5 |
BorgWarner
BWA
|
+$898K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Carlyle Group
CG
|
+$962K |
| 2 |
GeneDx Holdings
WGS
|
+$933K |
| 3 |
Viasat
VSAT
|
+$852K |
| 4 |
INFA
Informatica
INFA
|
+$807K |
| 5 |
Amgen
AMGN
|
+$804K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.61% |
| 2 | Technology | 17.16% |
| 3 | Industrials | 15.49% |
| 4 | Financials | 11.59% |
| 5 | Consumer Discretionary | 10.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Select Water Solutions
WTTR
$2.51B
| $436K | 0.2% |
+41,561
| New | +$504K |
|
152
Mirum Pharmaceuticals
MIRM
$6.89B
| $436K | 0.2% |
+9,675
| New | +$456K |
|
153
Mission Produce
AVO
$1.1B
| $435K | 0.2% |
41,516
+22,242
| +115% | +$259K |
|
154
Biogen
BIIB
$29.9B
| $435K | 0.2% |
3,179
+1,540
| +94% | +$220K |
|
155
Radian Group
RDN
$5.14B
| $432K | 0.2% |
13,072
-977
| -7% | -$31.8K |
|
156
Procter & Gamble
PG
$343B
| $430K | 0.2% |
+2,524
| New | +$423K |
|
157
Equity Bancshares
EQBK
$1.03B
| $429K | 0.2% |
10,891
+4,950
| +83% | +$208K |
|
158
ClearPoint Neuro
CLPT
$423M
| $429K | 0.2% |
+36,082
| New | +$561K |
|
159
Sea Limited
SE
$61.2B
| $427K | 0.2% |
+3,274
| New | +$406K |
|
160
Privia Health
PRVA
$3.21B
| $427K | 0.2% |
19,006
-2,360
| -11% | -$54.8K |
|
161
MKS Inc
MKSI
$22.2B
| $425K | 0.19% |
+5,304
| New | +$536K |
|
162
Harmony Biosciences
HRMY
$2.04B
| $424K | 0.19% |
12,770
-19,314
| -60% | -$692K |
|
163
American Eagle Outfitters
AEO
$2.85B
| $424K | 0.19% |
36,454
-7,860
| -18% | -$112K |
|
164
Amneal Pharmaceuticals
AMRX
$5.72B
| $423K | 0.19% |
+50,530
| New | +$422K |
|
165
ON Semiconductor
ON
$33.8B
| $421K | 0.19% |
+10,345
| New | +$521K |
|
166
10x Genomics
TXG
$5.87B
| $420K | 0.19% |
+48,137
| New | +$607K |
|
|
SEI
167
Solaris Energy Infrastructure
SEI
$3.31B
| $420K | 0.19% |
+19,300
| New | +$535K |
|
|
TPH
168
DELISTED
Tri Pointe Homes
TPH
| $420K | 0.19% |
+13,156
| New | +$449K |
|
169
Federal Realty Investment Trust
FRT
$10.9B
| $419K | 0.19% |
4,288
+1,727
| +67% | +$179K |
|
170
AbCellera Biologics
ABCL
$1.62B
| $419K | 0.19% |
187,822
+19,140
| +11% | +$54.9K |
|
171
FirstEnergy
FE
$28.9B
| $417K | 0.19% |
10,327
+203
| +2% | +$8.08K |
|
172
Alpha Metallurgical Resources
AMR
$1.82B
| $416K | 0.19% |
3,319
+1,206
| +57% | +$196K |
|
173
Xeris Biopharma Holdings
XERS
$1.44B
| $416K | 0.19% |
75,706
+22,946
| +43% | +$92.6K |
|
174
Regeneron Pharmaceuticals
REGN
$68.8B
| $414K | 0.19% |
653
+190
| +41% | +$131K |
|
175
Aspen Aerogels
ASPN
$387M
| $414K | 0.19% |
64,810
+35,999
| +125% | +$347K |
|
Similar funds
SFA
FCM
CPI
SW
MTIC
KFSC
YCM
SC
EntryPoint Capital's Q1 2025 Portfolio in Review
As of Q1 2025, EntryPoint Capital held 1,001 positions worth $218M, down 8.2% from $238M the previous quarter. Its ten largest holdings account for 4.4% of the portfolio.
EntryPoint Capital's Q1 2025 filing shows 307 new, 177 increased, 167 reduced and 349 closed positions. Its largest new stake was AtriCure: 25,168 shares worth $812K. The largest sale was Carlyle Group, an estimated $962K.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Industrials.
- EntryPoint Capital's largest Q1 2025 buy was AtriCure: 25,168 shares worth $812K.
- EntryPoint Capital added most to Amphenol in Q1 2025, an estimated $815K increase.
- EntryPoint Capital's biggest Q1 2025 reduction was Harmony Biosciences, cutting an estimated $692K.
- EntryPoint Capital fully exited Carlyle Group in Q1 2025, selling an estimated $962K.
- EntryPoint Capital's ten largest holdings make up 4.4% of its $218M portfolio in Q1 2025.
- EntryPoint Capital opened 307 new positions and closed 349 in Q1 2025.
- EntryPoint Capital's portfolio value fell 8.2% quarter-over-quarter to $218M.
Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.